Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CLPP | Q16740 | 10/20 | 0.51 |
| ▸ | GRM5 | P41594 | 2/20 | 0.47 |
| ▸ | PRLHR | P49683 | 2/20 | 0.43 |
| ▸ | TNKS | O95271 | 3/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.40 |
| ▸ | PDE9A | O76083 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22424384 | 0.94 | CLPP (0.51) | CLPPGRM5PRLHRTNKSTNKS2 | |
| SCHEMBL22424577 | 0.92 | CLPP (0.50) | CLPPGRM5PRLHRTNKSTNKS2 | |
| SCHEMBL22424333 | 0.91 | CLPP (0.54) | CLPPGRM5PRLHRHDAC6PDE9A | |
| SCHEMBL22424550 | 0.90 | CLPP (0.53) | CLPPGRM5PRLHRTNKSTNKS2 | |
| SCHEMBL22424585 | 0.89 | CLPP (0.52) | CLPPGRM5PRLHRHDAC6PARP1 | |
| SCHEMBL22424217 | 0.88 | CLPP (0.52) | CLPPGRM5PRLHRHDAC6PDE9A | |
| SCHEMBL22424581 | 0.85 | CLPP (0.52) | CLPPGRM5PRLHRTNKSTNKS2 | |
| SCHEMBL22424586 | 0.84 | CLPP (0.51) | CLPPGRM5PRLHRTNKSTNKS2 | |
| SCHEMBL22423946 | 0.83 | CLPP (0.50) | CLPPGRM5PRLHRPARP1PDE9A | |
| SCHEMBL22424698 | 0.82 | CLPP (0.49) | CLPPGRM5PRLHRTNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020182990-A1 | FUSED RING PYRIMIDONE DERIVATIVES FOR USE IN THE TREATMENT OF HBV INFECTION OR OF HBV-INDUCED DISEASES | Janssen Sciences Ireland Unlimited Company (IE) | 2020-09-17 | — | — | WO | disclosed |